Jeil Pharma Holdings Inc (KRX:002620)
7,350.00
+100.00 (1.38%)
Feb 20, 2025, 9:00 AM KST
Jeil Pharma Holdings Revenue
Jeil Pharma Holdings had revenue of 190.00B KRW in the quarter ending September 30, 2024, a decrease of -2.45%. This brings the company's revenue in the last twelve months to 778.79B, down -1.48% year-over-year. In the year 2023, Jeil Pharma Holdings had annual revenue of 804.04B with 1.40% growth.
Revenue (ttm)
778.79B
Revenue Growth
-1.48%
P/S Ratio
0.14
Revenue / Employee
22.25B
Employees
35
Market Cap
112.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 804.04B | 11.08B | 1.40% |
Dec 31, 2022 | 792.96B | 30.40B | 3.99% |
Dec 31, 2021 | 762.57B | 571.30M | 0.07% |
Dec 31, 2020 | 762.00B | 30.19B | 4.13% |
Dec 31, 2019 | 731.80B | 589.07B | 412.70% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 4,364.39B |
Celltrion | 2,876.25B |
Yuhan | 2,008.84B |
SK Biopharmaceuticals | 511.33B |
SK bioscience | 201.30B |
Hanmi Pharm. | 1,495.50B |
Hanmi Science | 1,283.65B |
Hanall Biopharma | 134.24B |